H172Y mutation perturbs the S1 pocket and nirmatrelvir binding of SARS-CoV-2 main protease through a nonnative hydrogen bond

Nirmatrelvir is an orally available inhibitor of SARS-CoV-2 main protease (Mpro) and the main ingredient of PAXLOVID, a drug approved by FDA for high-risk COVID-19 patients. Although the prevalent Mpro mutants in the SARS-CoV-2 Variants of Concern (e.g., Omicron) are still susceptible to nirmatrelvi...

Descripción completa

Detalles Bibliográficos
Autores principales: de Oliveira, Vinicius Martins, Ibrahim, Mohamed Fourad, Sun, Xinyuanyuan, Hilgenfeld, Rolf, Shen, Jana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Journal Experts 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9387537/
https://www.ncbi.nlm.nih.gov/pubmed/35982654
http://dx.doi.org/10.21203/rs.3.rs-1915291/v1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9387537/
https://www.ncbi.nlm.nih.gov/pubmed/35982654
http://dx.doi.org/10.21203/rs.3.rs-1915291/v1

Ejemplares similares